Name | Ibandronate sodium monohydrate |
Synonyms | Boniva Bonviva Ibandrate BM-21.0955 Ibadronate SodiuM Ibandromate Monosodium Ibandronate sodium monohydrate [1-Hydroxy-3-(methylpentylamino)-propylidene]bisphosphonic acid sodium salt [1-Hydroxy-3-(methylpentylamino)-propylidene]bisphosphonic acid sodium salt monohydrate sodium hydrogen {1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonate hydrate Sodium Trihydrogen (1-Hydroxy-3-(methylpenthylamino)propylidene)diphosphonate Monohydrate |
CAS | 138926-19-9 |
EINECS | 639-757-2 |
InChI | InChI=1/C9H23NO7P2.Na.H2O/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17;;/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17);;1H2/q;+1;/p-1 |
Molecular Formula | C9H24NNaO8P2 |
Molar Mass | 359.23 |
Melting Point | 840C (dec) |
Boling Point | 587.8°C at 760 mmHg |
Flash Point | 309.3°C |
Solubility | Soluble in water (72 mg/ml at 25 °C), ethanol (<1 mg/ml at 25 °C), and DMSO (<1 mg/ |
Vapor Presure | 2.88E-16mmHg at 25°C |
Appearance | White crystalline powder |
Color | White |
Storage Condition | Keep in dark place,Inert atmosphere,2-8°C |
Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
Sensitive | Sensitive to light |
Physical and Chemical Properties | White crystalline powder, soluble in water, insoluble in alcohol. |
Use | For the treatment of malignant hypercalcemia |
In vitro study | Ibronate (1.25-2 μm) significantly reduced endothelial cell growth, while ibronate (2 μm) also significantly reduced capillary-like lumen formation and increased endothelial cell apoptosis. Ibandronate (< 100 μm) dose-dependently increased VEGF expression in endothelial cells. Ibandronate (<100 μm) dose-dependently inhibited the growth of prostate cancer cell lines (LNCaP and PC-3). |
In vivo study | In women with osteoporosis treated for 3 years, Ibandronate is administered daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months) significantly reduced the risk of new-form vertebral fractures by 62% and 50% (p = 0.0006), respectively. In women with osteoporosis treated for 3 years, Ibandronate is administered daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months) significantly and progressively increased lumbar BMD by 6.5 and 5.7%, respectively. Ibandronate (< 125 mg/kg s.c.) caused a dose-dependent increase in bone density, cancellous bone volume, and trabecular bone number, failure load (Fmax), and yield load in long bones and vertebrae of ovariectomized rats, and the increased trabecular separation in ovariectomized rats could be completely prevented by any dose of Ibandronate. |
Hazard Symbols | Xn - Harmful |
Risk Codes | 40 - Limited evidence of a carcinogenic effect |
Safety Description | S22 - Do not breathe dust. S36 - Wear suitable protective clothing. S24/25 - Avoid contact with skin and eyes. |
HS Code | 29319090 |
biological activity | Ibandronate (BM-21.0955, BM-210955, RPR-102289A) is an efficient nitrogen-containing bisphosphonate used to treat osteoporosis. |
use | for the treatment of malignant hypercalcemia Inhibits bone resorption as a sodium salt and complexed with technetium Tc 99m for bone imaging. The monophosphonates are not active. Biphosphonates are used in disorders affecting the skeleton such a s asteoporosis, metastatic disease, and Paget holmium disease. |